-
Murlentamab: Revolutionizing Cancer Research with Targeted Therapy(Post)
Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst
Indusatumab: Advancing Anti-CD47 Cancer Research with Biosimilar Innovations(Post)Quick Facts About IndusatumabWhat is Indusatumab?Indusatumab is an experimental antibody therapy targeting CD47, a protein that enables cancer cells to evade immune destruction.How does
Tarextumab: Unlocking the Potential of Cancer Therapeutics(Post)Quick Facts About TarextumabWhat is Tarextumab?Tarextumab is a novel therapeutic antibody designed to target the Notch signaling pathway, which plays a crucial role in tumor progression
Natalizumab: Mechanism, Applications, and Emerging Research in Multiple Sclerosis and Crohn's Disease(Post)Quick Facts About NatalizumabWhat is Natalizumab?Natalizumab is a monoclonal antibody used to treat multiple sclerosis (MS) and Crohn's disease. It works by blocking immune cells from at
Lirilumab: Unlocking the Potential of Anti-KIR Therapy in Cancer Research(Post)Quick Facts About LirilumabWhat is Lirilumab?Lirilumab is an anti-KIR monoclonal antibody designed to enhance natural killer (NK) cell activity by blocking killer-cell immunoglobulin-lik
Emapalumab: Unlocking the Potential of Targeting IFN-γ in HLH Treatment(Post)Quick Facts About EmapalumabWhat is Emapalumab?Emapalumab is a fully human monoclonal antibody that neutralizes interferon-gamma (IFN-γ). It is the first FDA-approved therapy for primary
One Ligand, Two Receptors, Opposite Jobs: TNFR1 vs TNFR2(Post)Blocking TNF cures rheumatoid arthritis in some patients and triggers demyelination in others. That is not a dosing problem, and it is not a patient-selection problem. It is the direct consequence of
CD33 Marker: Function, Expression & Myeloid Cell Role(Post)Introduction Discover the multifaceted role of CD33, a critical player in immune function and disease, shaping our approach to treating cancers and neurodegenerative conditions
After Tocilizumab, IL-6 Goes Up. That Is the Drug Working.(Post)Tocilizumab reverses cytokine release syndrome within hours, and it never touches the cell that started it. That sentence contains the whole mechanism. The trigger is a T cell — engaged by a CAR, a b
Galegenimab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About GalegenimabWhat is Galegenimab?Galegenimab is an anti-CD47 monoclonal antibody designed to block the "don't eat me" signal, enhancing the immune system's ability to eli
Key Players in T Cell Regulation: Lag-3, Tim-3, and TIGIT(Post)Understanding Lag-3, Tim-3, and TIGIT: Key Players in T Cell RegulationThe immune system's ability to regulate T cell responses is crucial for maintaining homeostasis and combating diseases such as ca
CD52 Expression(Post)What is CD52? Cluster Of Differentiation 52 (CD52) is a highly expressed membrane glycoprotein which is present on the surface of immune cell
Co-Inhibitory Checkpoints Beyond PD-1: CTLA-4, LAG-3 and TIM-3(Post)PD-1 gets the attention, but it is one brake among many — and the others do not work the same way. The co-inhibitory receptors are routinely drawn as interchangeable stop signs on a T cell. They are
Resources(Page) Flow Cytometry Gating: A Comprehensive Guide(Post)Techniques · Flow CytometryFlow Cytometry Gating: A Comprehensive GuideGating is how flow cytometry data is turned into meaningful results — a series of regions drawn on scatter and fluorescence plots
Your Th2 Phenotype Might Not Be a T Cell(Post)If your knockout showed a type 2 phenotype and you attributed it to Th2 cells, there is a reasonable chance you were looking at something else. Innate lymphoid cells run T-bet, GATA3 and RORγt — not
Secukinumab: A Comprehensive Guide to Its Mechanism, Applications, and Biosimilar Advancements(Post)Quick Facts About SecukinumabWhat is SecukinumabSecukinumab is a monoclonal antibody that targets interleukin-17A (IL-17A), a key cytokine involved in inflammatory and autoimmune respons
Cabiralizumab: Unlocking the Potential of Anti-CSF1R Therapy(Post)What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c
Bevacizumab: Mechanism, Clinical Applications, and Biosimilar Insights(Post)Quick Facts About BevacizumabWhat is Bevacizumab?Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis (the formation of ne
Avdoralimab: Exploring Its Role in Immunotherapy and Biosimilar Advancements(Post)Quick Facts About AvdoralimabWhat is Avdoralimab?Avdoralimab is a monoclonal antibody targeting C5aR1, playing a crucial role in modulating immune response and inflammation.What is the m